BioNTech (BNTX) COO Poetting details initial share and option holdings

Rhea-AI Filing Summary

BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares. He holds options and phantom options over 18,416, 25,459, 8,838, 7,112 and 14,664 underlying ordinary shares with exercise prices including 113.9400, 185.2300 and 152.1000, expiring between 2031 and 2035. He also reports 11,047 performance share units tied to ordinary shares. In addition, he has 141,514 ordinary shares directly, 449,387 ordinary shares held through Tofino GmbH, where he is sole shareholder, and 1,638 ordinary shares held by immediate family, for which he disclaims beneficial ownership except for any pecuniary interest.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Poetting Sierk

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	449,387	I	See Footnote(1)
Ordinary Shares	141,514	D
Ordinary Shares	1,638	I	See Footnote(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	05/22/2027(3)	05/22/2033	Ordinary Shares(4)	18,416	$113.94(5)	D
Option (right to buy)	08/26/2028(3)	08/26/2034	Ordinary Shares(4)	25,459	(5)(6)	D
Option (right to buy)	05/28/2029(3)	05/28/2035	Ordinary Shares(4)	8,838	(5)(7)	D
Phantom Option	05/12/2025(3)	05/12/2031	Ordinary Shares(8)	7,112	$185.23(5)	D
Phantom Option	05/31/2026(3)	05/31/2032	Ordinary Shares(8)	14,664	$152.1(5)	D
Performance Share Unit	05/27/2029(9)	05/27/2035	Ordinary Shares(9)	11,047	$0	D

Explanation of Responses:

1. The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH.

2. The ordinary shares are held by the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the ordinary shares noted herein except to the extent of his pecuniary interest therein.

3. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

4. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

5. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

6. The exercise price of this option is EUR 75.91.

7. The exercise price of this option is EUR 93.35.

8. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.

9. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioNTech (BNTX) COO Sierk Poetting report in this Form 3?

Sierk Poetting reports his initial ownership in BioNTech, including direct, indirect and derivative interests in ordinary shares. The filing details option grants, phantom options, performance share units and ordinary shares held directly, via Tofino GmbH, and by immediate family members.

How many BioNTech (BNTX) ordinary shares does Sierk Poetting hold directly and indirectly?

He reports 141,514 ordinary shares held directly. Indirectly, 449,387 ordinary shares are held by Tofino GmbH, where he is the sole shareholder, and 1,638 ordinary shares are held by his immediate family, with beneficial ownership disclaimed except for any pecuniary interest.

What option and phantom option positions does the BioNTech (BNTX) COO disclose?

He reports options over 18,416, 25,459 and 8,838 underlying ordinary shares, with exercise prices including 113.9400 and 0.0000, and expirations between 2033 and 2035. He also lists phantom options over 7,112 and 14,664 underlying ordinary shares, expiring in 2031 and 2032.

How are BioNTech (BNTX) performance share units structured for Sierk Poetting?

He reports 11,047 performance share units, each economically equivalent to one ordinary share. They can settle in ordinary shares, ADSs or cash and vest annually over four years, subject to performance targets and his continued service through applicable dates.

Are any of the BioNTech (BNTX) holdings in this Form 3 new share purchases or sales?

The Form 3 lists holdings rather than new purchases or sales. All transactions are classified as holdings with unknown transaction codes, reflecting Poetting’s existing positions in shares, options, phantom options and performance share units at the time of filing.

What do the footnotes reveal about BioNTech (BNTX) COO Sierk Poetting’s indirect holdings?

Footnotes state that ordinary shares are held by Tofino GmbH, where he is sole shareholder and may be deemed beneficial owner, and by his immediate family. He disclaims beneficial ownership of family-held shares except to the extent of his pecuniary interest.